Bidirectional pharmacokinetic drug interactions between olaparib and metformin.

ABSTRACT:

Objective

Olaparib is a PARP (poly-ADP-ribose polymerase) inhibitor used for maintenance therapy in BRCA-mutated cancers. Metformin is a first-choice drug used in the treatment of type 2 diabetes. Both drugs are commonly co-administered to oncologic patients with add-on type 2 diabetes mellitus. Olaparib is metabolized by the CYP3A4 enzyme, which may be inhibited by metformin through the Pregnane X Receptor. In vitro studies have shown that olaparib inhibits the following metformin transporters: OCT1, MATE1, and MATE2K. The aim of the study was to assess the influence of 'the perpetrator drug' on the pharmacokinetic (PK) parameters of 'the victim drug' after a single dose. To evaluate the effect, the AUC_0→∞ (area under the curve) ratio was determined (the ratio between A

SUBMITTER: Stanislawiak-Rudowicz J 

PROVIDER: S-EPMC10796410 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature